Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα

Objective Chronic HCV infection is characterised by innate immune activation with increased interferon-stimulated genes (ISG) expression and by an altered phenotype of interferon-responsive natural killer (NK) cells. Here, we asked whether a rapid reduction in viremia by daclatasvir (DCV) and asunaprevir (ASV) improves the response to pegylated interferon (PegIFN) in patients who had previously failed a standard course of PegIFN/ribavirin (RBV) therapy. Design Twenty-two HCV-infected non-responders to previous PegIFN/RBV therapy were studied for IFN-responsiveness of NK cells during quadruple (QUAD) therapy with DCV, ASV, PegIFN and RBV. A direct comparison of early NK cell responses in PegIFN/RBV therapy and QUAD therapy was performed for seven patients using paired cryopreserved peripheral blood mononuclear cells (PBMC) from both treatment courses. As a validation cohort, nine DCV/ASV-treated patients were studied for their NK cell response to in vitro stimulation with IFNα. Results The 24 h virological response to QUAD therapy correlated with an increase in signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1 (pSTAT1) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in NK cells, and the STAT1/pSTAT1/TRAIL induction was greater during QUAD therapy than during previous PegIFN/RBV therapy. Successful QUAD therapy as well as successful IFN-free DCV/ASV regimen resulted in an improved functional NK cell response (degranulation and TRAIL expression) to in vitro stimulation with IFNα. Conclusions IFN-responsiveness can be improved by inhibiting HCV replication and reducing the HCV-induced activation of the innate immune response. This may provide a rationale for clinical trials of a brief period of direct acting antiviral therapy followed by PegIFN/RBV therapy to reduce the overall treatment costs in low-income and middle-income countries. Trial registration numbers NCT01888900 and NCT00718172.

[1]  R. D. de Knegt,et al.  Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. , 2016, The Journal of infectious diseases.

[2]  E. Barnes,et al.  Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. , 2015, Gastroenterology.

[3]  M. Manns,et al.  Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism , 2015, Journal of leukocyte biology.

[4]  T. Liang,et al.  Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. , 2015, Gastroenterology.

[5]  S. Pol,et al.  Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. , 2015, Journal of hepatology.

[6]  Z. Kutalik,et al.  Correction: Corrigendum: Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[7]  Z. Kutalik,et al.  Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[8]  M. Heim,et al.  Innate and adaptive immune responses in HCV infections. , 2014, Journal of hepatology.

[9]  V. Lohmann,et al.  Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. , 2014, Gastroenterology.

[10]  N. Dixit,et al.  Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment , 2014, Nature Communications.

[11]  T. Baumert,et al.  IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies , 2014, The Journal of experimental medicine.

[12]  Julia E. Vogt,et al.  Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. , 2014, The Journal of clinical investigation.

[13]  A. Lok,et al.  Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. , 2014, Journal of hepatology.

[14]  C. Tinelli,et al.  Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. , 2013, Journal of hepatology.

[15]  B. Rehermann.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells , 2013, Nature Medicine.

[16]  T. Liang,et al.  Current and future therapies for hepatitis C virus infection. , 2013, The New England journal of medicine.

[17]  Kenji Ikeda,et al.  Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. , 2013, Journal of hepatology.

[18]  B. Gao,et al.  Interferon‐lambda (IFN‐λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes , 2013, Journal of leukocyte biology.

[19]  Barbara Rehermann,et al.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.

[20]  K. Chayama,et al.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.

[21]  B. Ursø,et al.  Cytotoxicity of CD56bright NK Cells towards Autologous Activated CD4+ T Cells Is Mediated through NKG2D, LFA-1 and TRAIL and Dampened via CD94/NKG2A , 2012, PloS one.

[22]  Anna Persson,et al.  Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.

[23]  T. Liang,et al.  Early changes in interferon signaling define natural killer cell response and refractoriness to interferon‐based therapy of hepatitis C patients , 2012, Hepatology.

[24]  Milton W. Taylor,et al.  Natural killer inhibitory receptor expression associated with treatment failure and interleukin‐28B genotype in patients with chronic hepatitis C , 2011, Hepatology.

[25]  T. Liang,et al.  Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. , 2011, Gastroenterology.

[26]  D. Olive,et al.  Activating NK cell receptor expression/function (NKp30, NKp46, DNAM‐1) during chronic viraemic HCV infection is associated with the outcome of combined treatment , 2011, European journal of immunology.

[27]  D. Tough,et al.  Interferon‐β and interferon‐λ signaling is not affected by interferon‐induced refractoriness to interferon‐α in vivo , 2011, Hepatology.

[28]  L. Moretta.  Dissecting CD56dim human NK cells. , 2010, Blood.

[29]  N. Hayashi,et al.  Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. , 2010, Journal of hepatology.

[30]  Hans-Gustaf Ljunggren,et al.  Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. , 2010, Gastroenterology.

[31]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[32]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[33]  G. Michelone,et al.  Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. , 2009, Gastroenterology.

[34]  Y.‐J. Wang,et al.  Natural killer cells suppress full cycle HCV infection of human hepatocytes , 2008, Journal of viral hepatitis.

[35]  Edward J Oakeley,et al.  Interferon signaling and treatment outcome in chronic hepatitis C , 2008, Proceedings of the National Academy of Sciences.

[36]  J. Glass,et al.  Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[37]  J. Hoofnagle,et al.  Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. , 2010, Gastroenterology.